[{"orgOrder":0,"company":"Caszyme","sponsor":"Integra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"LITHUANIA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Cell and Gene Therapy","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Caszyme","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Caszyme \/ Integra Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Caszyme \/ Integra Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Caszyme

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The agreement aims for the use of Caszyme's novel Cas12l nucleases to develop safer and more efficient gene and cell therapies.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 04, 2024

                          Lead Product(s) : Cell and Gene Therapy

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Integra Therapeutics

                          Deal Size : $42.0 million

                          Deal Type : Licensing Agreement

                          blank